Recent evidence suggests that IL-17 induces collagen deposition in the ECM, shielding tumor cells from immune attack and conferring resistance to anti-PD-1/PD-L1 therapy in squamous cell carcinoma (Chen et al., 2022). Here, IL17A is linked to neoplasm.